Cryo-Cell International (NYSEAMERICAN:CCEL) is a leading cord blood bank specializing in the collection, processing and long-term cryogenic storage of umbilical cord blood and tissue stem cells. Founded in 1989 and headquartered in Oldsmar, Florida, the company was among the first to commercialize private family stem cell banking in the United States. Over three decades, it has refined proprietary processing methods aimed at maximizing stem cell viability, offering families a resource for regenerative therapies and future medical treatments.
The company’s core services encompass collection of cord blood and tissue immediately after childbirth, comprehensive laboratory testing to verify sample integrity, and secure cryogenic preservation within state-of-the-art storage facilities. Beyond its flagship cord blood program, Cryo-Cell has expanded to include placental tissue banking and companion diagnostic offerings, supporting clinical research in hematology, immunotherapy and personalized medicine.
Through a network of licensed collection centers and strategic affiliates across North America, Europe and Asia, Cryo-Cell International serves clients in more than 20 countries. The firm adheres to stringent regulatory standards set by the U.S. Food and Drug Administration and the American Association of Tissue Banks, as well as international quality accreditations, to ensure best-in-class handling and storage protocols.
Led by a multidisciplinary team of medical professionals and industry executives, Cryo-Cell continues to advance its processing platforms through ongoing research and development initiatives. By combining clinical expertise with robust logistics and customer-service infrastructure, the company aims to remain at the forefront of regenerative medicine, delivering accessible, high-quality biobanking solutions to families and healthcare providers worldwide.
